<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462082</url>
  </required_header>
  <id_info>
    <org_study_id>17-5785</org_study_id>
    <nct_id>NCT03462082</nct_id>
  </id_info>
  <brief_title>Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease</brief_title>
  <official_title>A Single-center, Randomized, Double-blinded, Double-crossover Trial of Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, randomized, quadruple-blinded, double-crossover comparative efficacy
      trial will study the effects of unilateral 50% voltage reduction in axial motor dysfunction
      for patients with Parkinson's disease that develop treatment-resistant postural stability
      gait dysfunction after bilateral subthalamic nucleus deep brain stimulation surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Actual">April 15, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in gait velocity</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>As measured during the 10-meter walk test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in postural instability gait dysfunction (1)</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>As measured by the mini-BESTest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postural instability gait dysfunction (2)</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>As measured by the UPDRS-PIGD subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postural instability gait dysfunction (3)</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>Quantitatively measured by the Zeno walkway</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in freezing of gait</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>As measured by the freezing of gait questionnaire and the Zeno walkway</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in speech dysfunction</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>As measured by the Praat software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the MDS-UPDRS</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>As measured by the total and motor scores of the MDS-UPDRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive tasks</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>As measured by selected cognitive tests sensitive for brain hemispheric lateralization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline and 3 to 4 weeks after randomization to each of the 3 study arms</time_frame>
    <description>As measured by the 39-item Parkinson's disease questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Baseline STN-DBS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Maintenance of baseline bilateral STN-DBS settings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymmetric STN-DBS 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unilateral 50% reduction of voltage (e.g. right side)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymmetric STN-DBS 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unilateral 50% reduction of voltage (e.g. left side)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Asymmetric STN-DBS</intervention_name>
    <description>Asymmetric deep brain stimulation</description>
    <arm_group_label>Asymmetric STN-DBS 1</arm_group_label>
    <arm_group_label>Asymmetric STN-DBS 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Parkinson's disease (PD) (previously diagnosed according to the UK brain
             bank criteria) who develop treatment-resistant postural instability gait dysfunction
             (PIGD) more than 6 months but less than 5 years after bilateral subthalamic nucleus
             deep brain stimulation (STN-DBS).

          -  Treatment-resistant PIGD will be defined as freezing of gait and UPDRS or MDS-UPDRS
             PIGD subscales of more than 6 points despite optimization of medications and bilateral
             STN-DBS programming.

        Exclusion Criteria:

          -  Treatment-resistant PIGD less than 6 months or more than 5 years after STN-DBS
             surgery.

          -  PIGD responsive to optimization of medications and/or bilateral STN-DBS programming.

          -  Cognitive impairment or psychiatric comorbidities (including substance abuse) that
             would interfere with the informed consent process, study adherence or outcome
             assessments.

          -  Advanced PD or any other neurological, cardiovascular or musculoskeletal
             co-morbidities that would preclude or require assistance to complete the 10-meter
             walking test.

          -  Patients not able to comply with 4-week interval evaluations following their potential
             enrollment due to personal reasons.

          -  Serious illness (requiring systemic treatment and/or hospitalization) until subject
             either completes therapy or is clinically-stable on therapy, in the opinion of the
             site investigator, for at least 30 days prior to study entry.

          -  Inability or unwillingness of subject or legal guardian/representative to give written
             informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Fasano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Movement disorders Centre, Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Fasano A, Herzog J, Seifert E, Stolze H, Falk D, Reese R, Volkmann J, Deuschl G. Modulation of gait coordination by subthalamic stimulation improves freezing of gait. Mov Disord. 2011 Apr;26(5):844-51. doi: 10.1002/mds.23583. Epub 2011 Mar 2.</citation>
    <PMID>21370271</PMID>
  </reference>
  <reference>
    <citation>Lizarraga KJ, Jagid JR, Luca CC. Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation on gait kinematics in Parkinson's disease: a randomized, blinded study. J Neurol. 2016 Aug;263(8):1652-6. doi: 10.1007/s00415-016-8191-3. Epub 2016 Jun 8.</citation>
    <PMID>27278062</PMID>
  </reference>
  <reference>
    <citation>Lizarraga KJ, Luca CC, De Salles A, Gorgulho A, Lang AE, Fasano A. Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. Surg Neurol Int. 2017 Oct 24;8:261. doi: 10.4103/sni.sni_292_17. eCollection 2017. Review.</citation>
    <PMID>29184712</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Alfonso Fasano</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>axial motor dysfunction</keyword>
  <keyword>asymmetric neuromodulation</keyword>
  <keyword>subthalamic nucleus deep brain stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To be shared as supplementary data upon publication of the results of the trial.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>To be shared as supplementary data upon publication of the results of the trial.</ipd_time_frame>
  </patient_data>
  <pending_results>
    <submitted>April 27, 2020</submitted>
    <returned>May 22, 2020</returned>
    <submitted>July 22, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

